Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ZIEXTENZO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6MG/0.6ML [SIN17604P]

Active ingredients: PEGFILGRASTIM

View product's general information
Last updated on 9 October 2026

Product Info

ZIEXTENZO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6MG/0.6ML

[SIN17604P]

Product information

Active Ingredient and Strength

PEGFILGRASTIM - 6 MG/0.6 ML

Dosage Form

INJECTION, SOLUTION

Manufacturer and Country

NOVARTIS PHARMACEUTICAL MANUFACTURING GMBH - AUSTRIA

Registration Number

SIN17604P

Licence Holder

SANDOZ SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L03AA13

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Dosing

4.2 Posology and method of administration
Adults (≥ 18 years): One 6 mg dose (a single pre-filled syringe) of pegfilgrastim is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy.

Ziextenzo therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.

Special populations
Pediatric Use
There are insufficient data to recommend the use of pegfilgrastim in children and adolescents under 18 years of age.

Geriatric Use
See section 5.2 (Pharmacokinetics in Special Populations) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Renal Impairment
See section 5.2 (Pharmacokinetics in Special Populations) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Hepatic Impairment
See section 5.2 (Pharmacokinetics in Special Populations) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Method of administration
Ziextenzo is for subcutaneous use.

Contraindications

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.